Pulmonx Corporation Announces Earnings Release and Conference Call for Fourth Quarter and Full Year 2024 Results
Redwood City, CA, February 5, 2025 – Pulmonx Corporation (Nasdaq: LUNG), a pioneering company in the field of minimally invasive treatments for lung diseases, recently announced that it will publish its financial results for the fourth quarter and the full year of 2024. The company will release these figures after the close of trading on Wednesday, February 19, 2025.
Impact on Pulmonx Shareholders
The release of Pulmonx’s financial results for the fourth quarter and full year 2024 is a significant event for the company’s shareholders. This announcement gives investors an opportunity to assess the financial performance of the company during this period and evaluate its progress towards achieving its business objectives. A strong earnings report could potentially lead to an increase in the stock price, while weak results might result in a decline.
Conference Call Details
Following the release of the financial results, Pulmonx management will host a conference call to discuss the details of the financial performance and answer questions from investors. The conference call is scheduled to begin at 1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET) on Wednesday, February 19, 2025. Interested investors can participate in the conference call by dialing the following numbers:
- Participant Dial-in (U.S.): (877) 407-4018
- Participant Dial-in (International): (201) 689-8562
- Conference ID: 1373128
Impact on the Lung Disease Treatment Industry
The financial results and conference call from Pulmonx Corporation could also have broader implications for the lung disease treatment industry as a whole. As a global leader in minimally invasive treatments for lung diseases, Pulmonx’s performance can serve as an indicator of the overall health and growth potential of the industry. A strong showing from Pulmonx could boost investor confidence in the sector and potentially attract more investment in research and development of new treatments for lung diseases.
Conclusion
The announcement from Pulmonx Corporation regarding the release of its financial results for the fourth quarter and full year 2024, along with the upcoming conference call to discuss these results, is an important event for the company’s shareholders and the lung disease treatment industry as a whole. The financial performance of Pulmonx during this period will offer insights into the company’s progress towards achieving its business objectives and the overall health of the lung disease treatment industry. Interested investors can participate in the conference call to gain further insights and ask questions about the company’s financial results.
